

daxibotulinumtoxin a-lanm (Daxxify®)

Medical Benefit Drug Policy

Place of Service

Office Administration

Drug Details

USP Category: Miscellaneous Therapeutic Agent

Mechanism of Action: Acetylcholine release inhibitor and neuromuscular blocking agent

HCPCS:

- Through 3/31/2024: C9160 per 1 unit
- Effective 4/1/2024 and after: J0589 Injection, daxibotulinumtoxina-lanm, 1 unit

How Supplied:

50 Units or 100 Units sterile lyophilized powder in a single-dose vial

Condition(s) listed in policy (*see coverage criteria for details*)

- Cervical dystonia / Spasmodic torticollis

The following condition(s) require Prior Authorization/Preservice:

Cervical dystonia / Spasmodic torticollis

1. Clonic or tonic involuntary contractions of multiple neck muscles exists, AND
2. Sustained head torsion and/or tilt with limited range of motion in the neck is present.

Covered Doses:

250 units given intramuscularly as a divided dose among affected muscles

Coverage Period:

Initial: One treatment every 12 weeks for 4 treatments

Reauthorization: Indefinite (if patient had clinical benefit)

References

1. AHFS. Available by subscription at <http://www.lexi.com>
2. DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
3. Daxxify (daxibotulinumtoxinA-lanm) [Prescribing information]. Newark, CA: Revance Therapeutics, Inc.; 8/2023.

Review History

daxibotulinumtoxin a-lanm (Daxxify®)



Date of Last Annual Review: 11/29/2023

Date of last revision: 1/3/2024

Changes from previous policy version:

- Added Effective 4/1/2024 and after: J0589 Injection, daxibotulinumtoxina-lanm, 1 unit

*Blue Shield of California Medication Policy to Determine Medical Necessity
Reviewed by P&T Committee*